Published in:
Open Access
01-12-2021 | Multiple Myeloma | Primary research
A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway
Authors:
Xuejie Gao, Bo Li, Anqi Ye, Houcai Wang, Yongsheng Xie, Dandan Yu, Zhijian Xu, Bingqing Shi, Hui Zhang, Qilin Feng, Ke Hu, Yong Zhang, Cheng Huang, Guang Yang, Jumei Shi, Weiliang Zhu
Published in:
Cancer Cell International
|
Issue 1/2021
Login to get access
Abstract
Background
Multiple myeloma (MM) is a highly aggressive and incurable clonal plasma cell disease with a high rate of recurrence. Thus, the development of new therapies is urgently needed. DCZ0805, a novel compound synthesized from osalmide and pterostilbene, has few observed side effects. In the current study, we intend to investigate the therapeutic effects of DCZ0805 in MM cells and elucidate the molecular mechanism underlying its anti-myeloma activity.
Methods
We used the Cell Counting Kit-8 assay, immunofluorescence staining, cell cycle assessment, apoptosis assay, western blot analysis, dual-luciferase reporter assay and a tumor xenograft mouse model to investigate the effect of DCZ0805 treatment both in vivo and in vitro.
Results
The results showed that DCZ0805 treatment arrested the cell at the G0/G1 phase and suppressed MM cells survival by inducing apoptosis via extrinsic and intrinsic pathways. DCZ0805 suppressed the NF-κB signaling pathway activation, which may have contributed to the inhibition of cell proliferation. DCZ0805 treatment remarkably reduced the tumor burden in the immunocompromised xenograft mouse model, with no obvious toxicity observed.
Conclusion
The findings of this study indicate that DCZ0805 can serve as a novel therapeutic agent for the treatment of MM.